Insider · CIK 0001762572

Hoitt Jason

Reports to the SEC for 3 companies · BEDFORD, MA

sec.gov

Transactions

Companies

Filings

CIK

0001762572

Forms 4 and 5

Insider transactions

33 trades

Date	Company	Role	Code	Shares	Price	Value	Shares after
2026-03-18	STOKStoke Therapeutics, Inc.S Sale	Chief Patient Officer	SSale	−30 sh	$32.85	−$985.5	10,276
2026-03-18	STOKStoke Therapeutics, Inc.S Sale	Chief Patient Officer	SSale	−1,762 sh	$31.28	−$55.1K	10,445
2026-03-18	STOKStoke Therapeutics, Inc.S Sale	Chief Patient Officer	SSale	−139 sh	$31.79	−$4,418.643	10,306
2026-03-17	STOKStoke Therapeutics, Inc.S Sale	Chief Patient Officer	SSale	−1,033 sh	$32.74	−$33.8K	12,955
2026-03-17	STOKStoke Therapeutics, Inc.S Sale	Chief Patient Officer	SSale	−748 sh	$33.38	−$25K	12,207
2026-03-15	STOKStoke Therapeutics, Inc.M Exercise/Conversion	Chief Patient Officer	MExercise/Conversion	+10K sh	—	—	13,988
2026-03-15	STOKStoke Therapeutics, Inc. · Restricted Stock UnitsM Exercise/Conversion	Chief Patient Officer	MExercise/Conversion	−10K sh	—	—	30,000
2026-02-17	STOKStoke Therapeutics, Inc. · Restricted Stock UnitsA Award	Chief Patient Officer	AAward	+48K sh	—	—	48,000
2026-02-17	STOKStoke Therapeutics, Inc. · Employee Stock Option (Right to Buy)A Award	Chief Patient Officer	AAward	+72K sh	—	—	72,000
2023-04-27	Provention Bio, Inc.Option to Purchase Common StockD Disposition to Issuer	Chief Commercial Officer	DDisposition to Issuer	−200K sh	—	—	0
2023-04-27	Provention Bio, Inc.Option to Purchase Common StockD Disposition to Issuer	Chief Commercial Officer	DDisposition to Issuer	−145K sh	—	—	0
2023-04-27	Provention Bio, Inc.Option to Purchase Common StockD Disposition to Issuer	Chief Commercial Officer	DDisposition to Issuer	−140K sh	—	—	0
2023-04-27	Provention Bio, Inc.Option to Purchase Common StockD Disposition to Issuer	Chief Commercial Officer	DDisposition to Issuer	−138K sh	—	—	0
2023-04-27	Provention Bio, Inc.Option to Purchase Common StockD Disposition to Issuer	Chief Commercial Officer	DDisposition to Issuer	−400K sh	—	—	0
2023-02-10	Provention Bio, Inc.S Sale	Chief Commercial Officer	SSale	−4,500 sh	$10.00	−$45K	0
2023-01-10	Provention Bio, Inc.Stock Option (right to buy)A Award	Chief Commercial Officer	AAward	+200K sh	—	—	200,000
2022-12-08	Provention Bio, Inc.Stock Option (right to buy)A Award	Chief Commercial Officer	AAward	+120K sh	—	—	340,000
2022-12-08	Provention Bio, Inc.Stock Option (right to buy)A Award	Chief Commercial Officer	AAward	+20.7K sh	—	—	75,763
2022-01-18	Provention Bio, Inc.Stock Option (right to buy)A Award	Chief Commercial Officer	AAward	+145K sh	—	—	145,000
2021-05-12	Provention Bio, Inc.Stock Option (right to buy)A Award	Chief Commercial Officer	AAward	+140K sh	—	—	139,500
2020-07-15	Provention Bio, Inc.Option (right to buy)A Award	Chief Commercial Officer	AAward	+138K sh	—	—	137,750
2020-03-19	Provention Bio, Inc.P Purchase	Chief Commercial Officer	PPurchase	+4,500 sh	$5.43	+$24.4K	4,500
2020-01-07	Provention Bio, Inc.Option (right to buy)A Award	Chief Commercial Officer	AAward	+400K sh	—	—	400,000
2019-11-12	Dova Pharmaceuticals Inc.Employee Stock Option (Right to Buy)D Disposition to Issuer	Chief Commercial Officer	DDisposition to Issuer	−250K sh	—	—	0
2019-11-12	Dova Pharmaceuticals Inc.D Disposition to Issuer	Chief Commercial Officer	DDisposition to Issuer	−9,970 sh	—	—	0
2019-09-30	Dova Pharmaceuticals Inc.S Sale	Chief Commercial Officer	SSale	−2,387 sh	$28.00	−$66.8K	9,970
2019-07-15	Dova Pharmaceuticals Inc.S Sale	Chief Commercial Officer	SSale	−900 sh	$16.44	−$14.8K	12,357
2019-07-15	Dova Pharmaceuticals Inc.S Sale	Chief Commercial Officer	SSale	−6,680 sh	$15.10	−$101K	13,257
2019-06-28	Dova Pharmaceuticals Inc.S Sale	Chief Commercial Officer	SSale	−2,237 sh	$13.77	−$30.8K	20,087
2019-06-28	Dova Pharmaceuticals Inc.S Sale	Chief Commercial Officer	SSale	−150 sh	$14.40	−$2,160	19,937
2019-04-08	Dova Pharmaceuticals Inc.S Sale	Chief Commercial Officer	SSale	−2,387 sh	$8.77	−$20.9K	22,324
2018-12-19	Dova Pharmaceuticals Inc.Employee Stock Option (right to buy)A Award	Chief Commercial Officer	AAward	+250K sh	—	—	250,000
2018-12-19	Dova Pharmaceuticals Inc.A Award	Chief Commercial Officer	AAward	+24.7K sh	—	—	24,711

Recent filings

Accepted (ET)
Mar 194
Hoitt Jason0001762572-26-000006
SEC(opens sec.gov)
Mar 174
Hoitt Jason0001762572-26-000004
SEC(opens sec.gov)
Feb 194
Hoitt Jason0001762572-26-000002
SEC(opens sec.gov)
Apr 274
Hoitt Jason0001493152-23-013904
SEC(opens sec.gov)
Feb 144
Hoitt Jason0001493152-23-005078
SEC(opens sec.gov)
Jan 114
Hoitt Jason0001493152-23-001208
SEC(opens sec.gov)
Dec 94
Hoitt Jason0001493152-22-035096
SEC(opens sec.gov)
Jan 204
Hoitt Jason0001493152-22-001752
SEC(opens sec.gov)
May 144
Hoitt Jason0001493152-21-011579
SEC(opens sec.gov)

Companies

Address

C/O STOKE THERAPEUTICS, INC. 45 WIGGINS AVENUE

BEDFORD, MA, 01730